Navigation Links
Shanghai ChemPartner Announces Being Selected as Antibody Service Partner by Shenogen Pharma Group
Date:3/16/2011

SHANGHAI, March 16, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its wholly-owned contract research subsidiary, Shanghai ChemPartner, has signed an outsource research service agreement with Shenogen Pharma Group to develop therapeutic monoclonal antibodies targeting the ER-alpha 36 receptor for cancer treatment.  Shenogen Pharma Group is a China-based drug development venture that develops innovative therapeutics for the treatment of oncology indications including breast cancer and leukemia.

"We have evaluated multiple potential antibody development service partners in China," said Dr. Xueming Qian, who joined Shenogen as Vice President of Biology and Antibody Technology last June after working for twelve years in Amgen's discovery research group at its Thousand Oaks, California site.  "We decided to work with ChemPartner's Biologics Services team because they have the required therapeutic antibody drug research and development experience, expertise and people to support our therapeutic antibody program."

ChemPartner will be responsible for a spectrum of drug discovery activities for an integrated antibody drug development program including target protein production and cell line development, lead antibody generation and optimization (humanization and affinity maturation), assay development, protein analytics, DMPK, and in vivo pharmacology.

Dr. Chengbin Wu, Vice President of Biologics Services of ChemPartner, added, "We are delighted that Shenogen, an innovative drug development company, chose ChemPartner as its preferred outsource partner for antibody drug development.  Shenogen has a world-class management team and exclusive global intellectual property rights on a novel target (ER-alpha 36), and we fully anticipate that ChemPartner's outsource service will facilitate the rapid advancement of Shenogen's antibody pipeline projects into development stage and beyond."

About Shenogen Pharma GroupShenogen Pharma Group is a privately held drug development venture that develops novel therapeutics targeting a membrane-bound estrogen receptor, ER-alpha 36, for the treatment of oncology indications. Shenogen collaborates extensively with key U.S. and China-based research and development partners to advance its pipeline projects. Shenogen has a pipeline of small molecule and antibody therapeutics, and its first lead compound is being evaluated in phase I clinical trial for oncology indications. For more information, please visit www.shenogen.com.cn.

About ShangPharma CorporationShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.ShangPharma CorporationLan Xie, VP of Finance and OperationsIR@shangpharma.comorChristensenIn New YorkKimberly Minarovich, +1-917-533-3268kminarovich@christensenir.comorIn Hong KongTip Fleming, +852-9212-0684tfleming@christensenir.com
'/>"/>

SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
2. American Scientific Resources Inc. Opens Shanghai Location
3. Shanghai ChemPartner Is Pleased to be Part of Agios Groundbreaking Cancer Research
4. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
5. China-Biotics to Host Investor Day in Shanghai to Discuss Corporate Development Strategy
6. Shanghai SynTheAll Pharmaceuticals Co., Ltd. (STA) Receives ISO 14001 Certification
7. Special Event Providing Exclusive Access to Shanghais Booming Zhangjiang Pharma Valley Added to Agenda of First Annual SBS China Conference
8. Winner Medical and Cotton Inc. Promote PurCotton(R) Brand and Natural(TM) Trademark in Shanghai
9. NSF International Opens NSF Shanghai Testing Laboratory in China to Support Increasing Demand for Testing and Certification Services
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... Calif. , June 14, 2017 The ... the City of Fremont and ... of the bio-pharma industry in California ... technology, enabling executive networking, and fostering workforce development. The ... development and growth of start-ups, as well as small ...
(Date:6/12/2017)... , June 12, 2017 Kineta, Inc., a ... announced Kineta Vice President of R&D and Head ... the Pandemic Preparedness for the Northwest and Beyond ... held on June 14, 2017 from 8:30-10:30 AM PDT at ... Dr. Bedard will be joined by ...
(Date:6/9/2017)... AirXpanders, Inc. (ASX: AXP) (AirXpanders or Company), ... sale and distribution of the AeroForm® Tissue Expander System, ... commercial roll-out in the United States ... hundred (100) medical institutions and health systems, located throughout ... alternative for women who choose reconstructive surgery following a ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... 2017 , ... After months of negotiations, FaceCradle USA is proud to announce the debut of ... , “Introducing our product on QVC is something we all worked hard to achieve for ... more than 90 million homes in the United States,” said FaceCradle USA President Dylan Doherty. ...
(Date:6/20/2017)... ... 20, 2017 , ... Hayes, Inc., a leading provider of ... “ 5 Questions to Ask Before Entering the Maze of Genetic Testing .” ... (GTE) team, the book explores the various types of the more than 65,000 ...
(Date:6/20/2017)... , ... June 20, 2017 , ... Kenneth Mayer, MD, ... Society (JIAS). , Dr. Mayer, who joined the JIAS Editorial Board in 2016, ... founding Medical Research Director of Fenway Health and Co-Chair of The Fenway ...
(Date:6/20/2017)... ... June 20, 2017 , ... HOUSTON – Brazos Towers at Bayou ... host of new options for today’s modern senior. Brazos Towers at Bayou Manor has ... they love while offering them the services to support that lifestyle both now and ...
(Date:6/20/2017)... SAN DIEGO, California (PRWEB) , ... June 20, ... ... modern product documentation and help content solutions for the enterprise, is proud to ... web properties, including CRM, e-commerce, ticketing systems, company websites, and more to provide ...
Breaking Medicine News(10 mins):